Investing.com -- Healthcare stocks in the U.S. and Europe have tumbled since Donald Trump’s election victory on November 5, with concerns rising over the potential policy impact of his cabinet picks, according toThe nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services has sparked sharp reactions, especially in pharmaceutical and biotech stocks.
Kennedy’s statements against GLP-1 drugs for obesity, vaccines, and broader FDA policies have raised alarms.NVO Barclays views the commercial market, rather than Medicaid or Medicare, as the primary growth driver for anti-obesity medications.) as stocks that have been “unduly punished” in response to Kennedy's nomination. Barclays has reiterated"overweight" ratings for both companies, viewing the selloff as an overreaction.
Beyond Kennedy’s nomination, Trump’s broader cabinet appointments, including Vivek Ramaswamy to the Department of Government Efficiency, have added to investor concerns about regulatory uncertainty.Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors.